Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cellular immune response

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    290 result(s) found for: Cellular immune response. Displaying page 1 of 15.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2008-004489-23 Sponsor Protocol Number: NVI-248 Start Date*: 2008-10-20
    Sponsor Name:Netherlands Vaccine Institute
    Full Title: Development of cellular immune response after infant pneumococcal conjugate vaccinations
    Medical condition: Cellular immune response(long term memory) after following the infant immunisation programme with a pneumococcal conjugate vaccine (Prevenar).
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2012-004486-41 Sponsor Protocol Number: 20130401 Start Date*: 2013-01-29
    Sponsor Name:Karolinska University Hospital, Huddinge, Sweden
    Full Title: Vaccination of antibody deficient patients with Prevenar13 - a comparative study between antibody response and cellular immunity.
    Medical condition: Patients with IgG-deficiency
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-003456-13 Sponsor Protocol Number: DEN-313 Start Date*: 2022-12-21
    Sponsor Name:Takeda Vaccines, Inc.
    Full Title: An Open Label, Phase 2 Study to Investigate Cell-mediated Immunity and Safety of a Tetravalent Dengue Vaccine Candidate (TDV) Administered Subcutaneously in Healthy Children Aged 4 to 16 Years
    Medical condition: Dengue fever
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10012312 Dengue fever virus infection LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-005672-34 Sponsor Protocol Number: FSME_only_1.1 Start Date*: 2013-03-05
    Sponsor Name:Institut für Spezifische Prophylaxe
    Full Title: Application of FSME-Immun® in allergic patients
    Medical condition: Allergic patients have generally an altered immune-responsiveness (Th2 bias), and allergic individuals undergoing de-sensitization display an increased production of immune supressive cytokines. We...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2021-004891-33 Sponsor Protocol Number: T33/2021 Start Date*: 2022-04-13
    Sponsor Name:Turku University Hospital
    Full Title: COVID-19 vaccine induced immune response in patients with primary antibody deficiency
    Medical condition: COVID-19
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002014-14 Sponsor Protocol Number: COV-PBO-MO28 Start Date*: 2021-04-20
    Sponsor Name:Fakultní nemocnice Hradec Králové
    Full Title: Antibody and cellular response 28 days after the first dose of COVID-19 vaccine (Moderna) and then 33 weeks after the second dose and 8-12 weeks after the third dose in clinically stable patients w...
    Medical condition: Antibody and cellular response 28 days after the first dose of COVID-19 vaccine (Moderna) and then 33 weeks after the second dose and 8-12 weeks after the third dose in clinically stable patients w...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001453-74 Sponsor Protocol Number: Version01.1. Start Date*: 2012-05-15
    Sponsor Name:Institute of Specific Prophylaxis and Tropical Medicine
    Full Title: Comparison of vaccination routes: subcutaneus versus intramuscular application of FSME-Immun®
    Medical condition: TBE vaccine (FSME-Immun®) is registered for intra-muscular application. Due to medical reasons (e.g. anticoagulant therapy, adipositas) intra-muscular application is not always possible. The aim o...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-004419-14 Sponsor Protocol Number: T125/2020 Start Date*: 2021-10-18
    Sponsor Name:Turku University Hospital
    Full Title: COVID-19 infections in hospital personnel
    Medical condition: COVID-19
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000300-38 Sponsor Protocol Number: 001610 Start Date*: 2021-02-05
    Sponsor Name:Antwerp University Hospital
    Full Title: Vaccination against cOvid-19 In CancER patients under active treatment (Belgium, B-VOICE)
    Medical condition: Onco-hematological patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000570-19 Sponsor Protocol Number: TBE_obesity_1.1 Start Date*: 2014-07-11
    Sponsor Name:Institute of Specific Prophylaxis and Tropical Medicine
    Full Title: Applikation of FSME-IMMUN® in obese persons
    Medical condition: Studies have shown that obesity has a direct effect on the immune system and leads to immunosuppression, which leads to a susceptibility to infection. The aim of this study is to clarify if a modif...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-002541-37 Sponsor Protocol Number: O2019-1 Start Date*: 2019-10-09
    Sponsor Name:Region Örebro län
    Full Title: Primary TBE vaccination for the elderly
    Medical condition: Immune response to TBE vaccination
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: View results
    EudraCT Number: 2022-003041-35 Sponsor Protocol Number: TJB2224 Start Date*: 2022-10-20
    Sponsor Name:CHU de Liège
    Full Title: Impact of the immune system on response to inactivated influenza vaccine (IIV) in allogeneic stem cell recipients
    Medical condition: Allogeneic hematopoietic stem cell recipients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000765-12 Sponsor Protocol Number: MICORYX Start Date*: 2011-08-22
    Sponsor Name:Oryx GmbH & Co. KG
    Full Title: Phase I/IIa study of immunization with frameshift peptides administered with Montanide ISA-51 VG in patients with advanced MSI-H colorectal cancer
    Medical condition: advanced MSI-H colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-006754-31 Sponsor Protocol Number: 80101 Start Date*: 2022-03-22
    Sponsor Name:Leiden University Medical Center
    Full Title: Establishing immunogenicity and safety of needle-free intradermal delivery by nanoporous ceramic skin patch of mRNA SARS-CoV-2 vaccine as a revaccination strategy in healthy volunteers
    Medical condition: Safety and immunogenicity after revaccination with Spikevax in healthy adults who have received Comirnaty as a primary vaccine
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-002928-41 Sponsor Protocol Number: Immunity_TBE Start Date*: 2013-01-14
    Sponsor Name:Med. Uni. Wien, Klinik für Innere I
    Full Title: Characterization of humoral and cellular immunity for tick-borne encephalitis (TBE) vaccination in allogeneic blood and marrow graft recipients: a pilot study
    Medical condition: Characterization of humoral and cellular immunity for tick-borne encephalitis (TBE) vaccination in allogeneic blood and marrow graft recipients: a pilot study Study group consists of patients 11...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2021-001357-31 Sponsor Protocol Number: IIV-478 Start Date*: 2021-05-03
    Sponsor Name:National Institute of Health and the Environment
    Full Title: Immune Responses Induced by Vaccination Against COVID-19 in Dutch healthy subjects
    Medical condition: Immune Responses Induced by Vaccination Against COVID-19 in Dutch healthy subjects
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2021-000413-17 Sponsor Protocol Number: COVERS Start Date*: 2021-02-24
    Sponsor Name:Region Skåne - Kliniska Studier Sverige, Forum Söder
    Full Title: COVERS (COVID-Vaccination Efficiency Risk and Safety Study) - an open trial for follow-up of efficacy, risk and safety in persons who have been vaccinated against SARS-CoV-2 in Region Skåne with va...
    Medical condition: Coronavirus disease 2019 (COVID-19)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001515-22 Sponsor Protocol Number: S54226 Start Date*: 2012-05-16
    Sponsor Name:Katholieke Universiteit Leuven
    Full Title: Cytomegalovirus infection and the influenza vaccination response in older persons
    Medical condition: Humoral and cellular immune response after vaccination in older people
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000683-30 Sponsor Protocol Number: CoVacc Start Date*: 2021-03-03
    Sponsor Name:Umeå university
    Full Title: CoVacc - Immune response to vaccination against Covid-19, an open multicenter phase IV study
    Medical condition: Individuals with and without pre-existing immunity to Covid-19.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2021-001040-10 Sponsor Protocol Number: CoVVac Start Date*: 2021-04-26
    Sponsor Name:Medical University of Graz
    Full Title: Humoral and cellular immune response to COVID-19 vaccines in immunocompromised and healthy individuals – The CoVVac study
    Medical condition: Active immunisation to prevent COVID-19 in immunocompromised individuals.
    Disease: Version SOC Term Classification Code Term Level
    23.1 10042613 - Surgical and medical procedures 10084457 COVID-19 immunisation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 20 12:56:15 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA